Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024


SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024.

Follow this link:
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

Related Posts